Valeant Pharmaceuticals International Sees Bausch & Lomb Acquisition as China Entry
Published: May 30, 2013
by Richard Daverman, PhD
May 29, 2013 -- Valeant Pharma, Canada’s largest drugmaker, announced yesterday it would pay $8.7 billion to acquire Bausch & Lomb. With the transaction, Valeant bought a substantial portfolio of eye care products, but it also acquired, for the first time, a sales foothold in China. Valeant said it would leverage B&L’s China organization to bring its own products to the PRC. More details....
Stock Symbol: (NYSE: VRX)
Help employers find you! Check out all the jobs and post your resume.